期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

过氧化体增殖物激活型受体基因变异与代谢综合征的相关性 被引量：2

下载PDF
导出
摘要 过氧化体增殖物激活型受体的活性与代谢综合征的各个组分密切相关。而过氧化体增殖物激活型受体基因变异可能导致代谢综合征的发生。过氧化体增殖物激活型受体α、γ、δ三个亚型的基因多态性与胰岛素抵抗、2型糖尿病、混合型高脂血症及肥胖密切相关。本文综述了相关文献资料,以期加强对过氧化体增殖物激活型受体基因多态性的认识,指导代谢综合征基因变异方面的基础理论研究。
作者 李东宝 华琦
机构地区 首都医科大学宣武医院心内科
出处 《中国动脉硬化杂志》 CAS CSCD 2007年第1期74-76,共3页 Chinese Journal of Arteriosclerosis
关键词 内科学 过氧化体增殖物激活型受体 基因变异 代谢综合征
分类号 R5 [医药卫生—内科学]
  • 相关文献

参考文献35

  • 1Gurnell M,Savage DB,Chatterjee VK,O'Rahilly S.The metabolic syndrome:peroxisome proliferator-activated receptor gamma and its therapeutic modulation[J].J Clin Endocrinol Metab,2003,88:2 412-421.
  • 2Meirhaeghe A,Amouyel P.Impact of genetic variation of PPAR gamma in humans[J].Mol Genet Metab,2004,83:93-102.
  • 3Miles PD,Barak Y,He W,Evans RM,Olefsky JM.Improved insulin sensitivity in mice heterozygous for PPARγ deficiency[J].J Clin Invest,2000,105:287-292.
  • 4Rosen ED,Sarraf P,Troy AE,Bradwin G,Moore K,Milstone DS,et al.PPAR gamma is reguired for the differentiation of adipose tissure in vivo and invitro[J].Mol Cell,1999,4:611-617.
  • 5Moon MK,Cho YM,Jung HS,Park YJ,Yoon KH,Sung YA,et al.Genetic polymorphisms in peroxisome proliferator-activated receptor gamma are associated with type 2 diabetes mellitus and obesity in the Korean population[J].Diabet Med,2005,22 (9):1 161-166.
  • 6Ghoussaini M,Meyre D,Lobbens S,Charpentier G,Clement K,Charles MA,et al.Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population[J].BMC Med Genet,2005,22 (6):11.
  • 7Ristow M,Muller Wieland D,Pfeiffer A,Krone W,Kahn CR.Obesity associated with a mutation in a genetic regulator of adipocyte differentiation[J].N Engl J Med,1998,339:953-959.
  • 8Swarbrick MM,Chapman CM,McQuillan BM,Hung J,Thompson PL,Beilby JP.A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity[J].Eur J Endocrinol,2001,144 (3):277-282.
  • 9Meirhaeghe A,Tanck MW,Fajas L,Janot C,Helbecque N,Cottel D,et al.Study of a new PPAR gamma2 promoter polymorphism and haplotype analysis in a French population[J].Mol Genet Metab,2005,85 (2):140-148.
  • 10Tanko LB,Siddiq A,Lecoeur C,Larsen PJ,Christiansen C,Walley A,et al.ACDC/adiponectin and PPAR-gamma gene polymorphisms:implications for features of obesity[J].Obes Res,2005,13 (12):2 113-121.

二级参考文献31

  • 1祝之明,周芳明,张刚,赵志钢,倪银星,祝善俊.代谢综合征心血管重塑的特征[J].中华心血管病杂志,2004,32(9):819-820. 被引量：41
  • 2Yen CJ,Beamer BA,Negri C,et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPARgamma2 missense mutation. Biochem Biophys Res Commun, 1997,241:270.
  • 3Mancini FP, Vaccaro O, Sabatino L, et al.Pro12Ala substitution in the peroxisome proliferator activated receptor gamma2 is not associated with type 2 diabetes. Diabetes, 2000,49:1 466.
  • 4Bluher M, Klemm T, Gerike T, et al. Lack of association between peroxisome proliferator activated receptor γ-2 gene variants and the occurrence of coronary heart disaese in patients with diabetes mellitus. European Journal of Endocrinology,2002, 146:545.
  • 5Ek J, Andersen G, Urhammer SA, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator activated receptor-γ2(PPARγ2) gene in relation to insulin sensitivity among glucose tolerant Cancasians. Diabetologia, 2001,44:1 170.
  • 6Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Bioche Biophy Res Commun, 2000,271:212.
  • 7Lee MC, Chao AH, Chen YDI, et al. Sibling-based association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese andJapanese hypertension families:a SAPPHIRe study. J Mol Med, 2001,79:656.
  • 8Zietz B, Barth N, Splegel D, et al.Pro12Ala polymorphism in the peroxisome proliferator activated receptor-γ2(PPARγ2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes, 2002,110:60.
  • 9Meirhaeghe A, Fajas L, Heibecque N, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord,2000,24:155.
  • 10Mori H,Ikegami H,Kawaguchi Y,et al. The Pro12Ala substitution in PPARγ is associated with resistance to development of diabetes in the general population. Diabetes, 2001,50:891.

共引文献15

同被引文献19

  • 1Ramos F, Baglivo HP, Ramirez AJ, et al. The metabolic syndrome and related eardlovaseulaa risk [J].Curr Hypertens Rep, 2001 3 (2) : 100-106.
  • 2Donnandy JA, Charbonnel B, Eckland DJA, et al.Secondary prevention of macrovasculm events in patients with type 2 diabetes in the PRO active sutdy ( PRO speetive pioglitazone clinical trial in macruvascular events):a randomised conu-olled trial [ J ]. Larwet, 2005,366 (9493) : 1 279-289.
  • 3Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of plo-glitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the P1OSTAT Study [J]. J Am Coll Cardiol, 2007, 49 (3) : 290-297.
  • 4Keech A, Simes RJ, Barter P, et al. Effects of long-term fenoflbrate ther- apy on cardiovascular events in 9795 people with type 2 diabetes menitus (the FIELD study) : randomised controlled trial[J]. Lancet, 2005, 366: 1 849-861.
  • 5Nakagawa T, Hu H, ZhmSkov S, et al. A causal role for uric acid in fructose-induced metabolicc syndrome [J].Am J Physiol Renal Physiol, 2006, 290 (3) : 625-531.
  • 6Rayssiguierl Y, Gueux E, Nowacki W, et al. High fiuetose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation [J].Magnesium Research, 2006, 19 (4) : 237-243.
  • 7Sharabi Y, Oron-Herman M, Kamafi Y, et al. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons fiom the high fructose fed rat model [J].Am J Hypertens, 2007, 20 (2) : 206- 210.
  • 8Peredo HA, Mayer MA, Caranza A, et al. Pioglltazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fiaactose-overloaded rats [J].Clin Exp Hypertens, 2008, 30 (2) : 159- 169.
  • 9Orasanu G, Ziouzenkova O. Devchand PR, et aJ. The perosisone prolif- erator-actlvated receptor-gamma agomist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitxu and in vivo in mice [J].J Am CoU Cardiol, 2008, 52 (10) : 869- 881.
  • 10Vosper H, Khoudoli GA, Graham TL, et al. Peroxisome proliferator-aetivated receptor agonists hyperlipidaemia, and athemsclerosis [J].Pharmacol Ther, 2002, 95 ( 1 ) : 4762.

引证文献2

二级引证文献5

中国动脉硬化杂志
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部